Immunocore IMCR Stock
Immunocore Price Chart
Immunocore IMCR Financial and Trading Overview
| Immunocore stock price | 30.16 USD |
| Previous Close | 57.76 USD |
| Open | 57.75 USD |
| Bid | 0 USD x 2900 |
| Ask | 0 USD x 900 |
| Day's Range | 56.46 - 58.5 USD |
| 52 Week Range | 29.16 - 69.06 USD |
| Volume | 152.19K USD |
| Avg. Volume | 256.77K USD |
| Market Cap | 2.68B USD |
| Beta (5Y Monthly) | 0.575598 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.02 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.62 USD |
IMCR Valuation Measures
| Enterprise Value | 2.53B USD |
| Trailing P/E | N/A |
| Forward P/E | -36.904457 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 16.15334 |
| Price/Book (mrq) | 10.227714 |
| Enterprise Value/Revenue | 15.229 |
| Enterprise Value/EBITDA | -68.94 |
Trading Information
Immunocore Stock Price History
| Beta (5Y Monthly) | 0.575598 |
| 52-Week Change | 74.88% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 69.06 USD |
| 52 Week Low | 29.16 USD |
| 50-Day Moving Average | 57.07 USD |
| 200-Day Moving Average | 55.27 USD |
IMCR Share Statistics
| Avg. Volume (3 month) | 256.77K USD |
| Avg. Daily Volume (10-Days) | 225.79K USD |
| Shares Outstanding | 46.23M |
| Float | 27.99M |
| Short Ratio | 9.78 |
| % Held by Insiders | 14.68% |
| % Held by Institutions | 69.28% |
| Shares Short | 2.69M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 5.82% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -25.20% |
| Operating Margin (ttm) | -24.44% |
| Gross Margin | 40.03% |
| EBITDA Margin | -22.089% |
Management Effectiveness
| Return on Assets (ttm) | -7.11% |
| Return on Equity (ttm) | -19.10% |
Income Statement
| Revenue (ttm) | 165.8M USD |
| Revenue Per Share (ttm) | 3.54 USD |
| Quarterly Revenue Growth (yoy) | 98.20% |
| Gross Profit (ttm) | 54.11M USD |
| EBITDA | -36627000 USD |
| Net Income Avi to Common (ttm) | -41793000 USD |
| Diluted EPS (ttm) | -1.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 337.46M USD |
| Total Cash Per Share (mrq) | 6.98 USD |
| Total Debt (mrq) | 68.14M USD |
| Total Debt/Equity (mrq) | 24.86 USD |
| Current Ratio (mrq) | 4.558 |
| Book Value Per Share (mrq) | 5.665 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 13.73M USD |
| Levered Free Cash Flow (ttm) | 18.34M USD |
Profile of Immunocore
| Country | United States |
| State | N/A |
| City | Abingdon |
| Address | 92 Park Drive |
| ZIP | OX14 4RY |
| Phone | 44 12 3543 8600 |
| Website | https://www.immunocore.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 408 |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Q&A For Immunocore Stock
What is a current IMCR stock price?
Immunocore IMCR stock price today per share is 30.16 USD.
How to purchase Immunocore stock?
You can buy IMCR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immunocore?
The stock symbol or ticker of Immunocore is IMCR.
Which industry does the Immunocore company belong to?
The Immunocore industry is Biotechnology.
How many shares does Immunocore have in circulation?
The max supply of Immunocore shares is 49.67M.
What is Immunocore Price to Earnings Ratio (PE Ratio)?
Immunocore PE Ratio is now.
What was Immunocore earnings per share over the trailing 12 months (TTM)?
Immunocore EPS is -1.02 USD over the trailing 12 months.
Which sector does the Immunocore company belong to?
The Immunocore sector is Healthcare.
Immunocore IMCR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}